New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (Obinutuzumab) for Primary Membranous Nephropathy (pMN). haga clic aquí for more information. Please visit our Patient Navigation tool for support.

RECURSOS

/

ENCUENTRA UN ESPECIALISTA

/

CONTACTO

Brian Kennedy

Brian Kennedy is a four-time Grammy Award–winning songwriter and producer, as well as a passionate advocate for rare kidney disease patients. Diagnosed with focal segmental glomerulosclerosis (FSGS) at the height of his music career, he later received a life-saving kidney transplant, an experience that now fuels his commitment to awareness, early detection, and health equity. Kennedy is the founder of Hits to Healing, a nonprofit dedicated to addressing health disparities through music, education, and community engagement. Drawing on both his personal journey and professional success, he brings a powerful voice and deep dedication to advancing NephCure’s mission.

Los Ángeles, California

Noticias relacionadas

NOTICIAS

The U.S. Food and Drug Administration Approves GAZYVA (obinutuzumab) as the First and Only Treatment for Primary Membranous Nephropathy

NOTICIAS

The FDA Grants Accelerated Approval of ULTOMIRIS (ravulizumab-cwvz) for Adults with IgA Nephropathy 

NOTICIAS

NephCure Applauds U.S. Department of Health and Human Services on the Release of the Rare Kidney Disease Inclusive Kidney Care National Plan

NOTICIAS

NephCure Celebrates C3G Awareness Day on September 25, 2026

Regístrese para recibir las últimas actualizaciones de NephCure.

INSCRIBIRSE
Este campo es para fines de validación y no debe modificarse.